You are here:

Abacavir/lamivudine combination (Kivexa®)


Following an abbreviated submission

Tablets delivering a fixed dose combination of abacavir 600mg and lamivudine 300mg are accepted for use in NHS Scotland for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults and adolescents over 12 years, in combination with other antiretroviral medicinal products. Both products are nucleoside reverse transcriptase inhibitors.

In patients for whom this combination is appropriate, it offers a single tablet at a lower cost per dose compared with the individual components.

Drug Details

Drug Name: Abacavir/lamivudine combination (Kivexa®)
SMC Drug ID: 175/05
Manufacturer: GlaxoSmithKline UK Ltd
Indication: HIV-1
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 9 May 2005